Scholarlink

<sup>Background</sup> <p><sup>89</sup>Zr is emerging as a popular positron-emitting radionuclide for imaging; however, its 909&#xa0;keV gamma emission presents shielding challenges, and radiation exposure safety guidelines for healthcare professionals working with the radionuclide have not been well-established. To guide assessment of the radiation risk and necessary safety guidelines, we present laboratory dose rate measurements of <sup>89</sup>Zr syringes and vials, and dose rates measurements made during the ZIRCON clinical trial ([<sup>89</sup>Zr]Zr-girentuximab) to evaluate healthcare provider exposure during administration, imaging, and surgical procedures.</p> Results <p>The maximum dose rate from a vial with no shielding was 0.334 µSv/h/MBq, and the minimum dose rate with 66&#xa0;mm lead shielding was 0.004 µSv/h/MBq. The controlled spill measured 0.52 µSv/h/MBq. Dose rates 1&#xa0;m from patients who received [<sup>89</sup>Zr]Zr-girentuximab had an average of 3.90 µSv/h at imaging. During surgery, waste measured below background levels, and a bed assistant 0.8&#xa0;m from the patient received a 5 µSv/h whole-body dose rate. The excised kidney measured 6 µSv/h at 5&#xa0;cm. </p> Conclusions <p>Our results demonstrate low radiation exposure levels associated with <sup>89</sup>Zr handling and exposure to the patient. With potential integration of <sup>89</sup>Zr into clinical practice, appropriate radiation safety guidelines are needed. Dose rate measurements can help guide development of best practices and site-specific protocols.</p> <p><i>Clinical trial number</i>: not applicable for this study; ZIRCON trial number NCT03849118, registered on 19 February 2019.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Radiation protection considerations with [89Zr]Zr-girentuximab PET and surgery

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月23日

查看全文
  • Adnan Chowdhury,
  • Clément Morgat,
  • Clement Bailly,
  • John Sunderland,
  • Stephen A. Graves,
  • Andrew M. Scott,
  • Sean Baker,
  • Beverley F. Holman

摘要

Background

89Zr is emerging as a popular positron-emitting radionuclide for imaging; however, its 909 keV gamma emission presents shielding challenges, and radiation exposure safety guidelines for healthcare professionals working with the radionuclide have not been well-established. To guide assessment of the radiation risk and necessary safety guidelines, we present laboratory dose rate measurements of 89Zr syringes and vials, and dose rates measurements made during the ZIRCON clinical trial ([89Zr]Zr-girentuximab) to evaluate healthcare provider exposure during administration, imaging, and surgical procedures.

Results

The maximum dose rate from a vial with no shielding was 0.334 µSv/h/MBq, and the minimum dose rate with 66 mm lead shielding was 0.004 µSv/h/MBq. The controlled spill measured 0.52 µSv/h/MBq. Dose rates 1 m from patients who received [89Zr]Zr-girentuximab had an average of 3.90 µSv/h at imaging. During surgery, waste measured below background levels, and a bed assistant 0.8 m from the patient received a 5 µSv/h whole-body dose rate. The excised kidney measured 6 µSv/h at 5 cm.

Conclusions

Our results demonstrate low radiation exposure levels associated with 89Zr handling and exposure to the patient. With potential integration of 89Zr into clinical practice, appropriate radiation safety guidelines are needed. Dose rate measurements can help guide development of best practices and site-specific protocols.

Clinical trial number: not applicable for this study; ZIRCON trial number NCT03849118, registered on 19 February 2019.